- Report
- April 2025
- 93 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- April 2025
- 94 Pages
Global
From €5324EUR$5,850USD£4,564GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- March 2025
- 175 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2025
- 200 Pages
Global
From €4086EUR$4,490USD£3,503GBP
- Report
- February 2024
- 99 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- July 2023
- 105 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Book
- January 2010
- 616 Pages
Verapamil is a calcium channel blocker used to treat high blood pressure, angina, and certain types of arrhythmia. It is a commonly prescribed cardiovascular drug, and is available in both oral and injectable forms. Verapamil works by blocking the influx of calcium into the cells of the heart and blood vessels, which helps to relax the muscles and reduce the workload of the heart. It is also used to treat cluster headaches and migraine headaches.
Verapamil is available in both generic and brand-name formulations. The brand-name versions include Calan, Isoptin, and Verelan. Generic versions are available from a variety of manufacturers.
In the Verapamil market, there are several major players, including Pfizer, Novartis, and Mylan. Other companies in the market include Teva Pharmaceuticals, Sandoz, and Sun Pharmaceuticals. Show Less Read more